Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + recombinant human endostatin
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Tislelizumab + recombinant human endostatin is a combination therapy being investigated for the treatment of non-small cell lung cancer (NSCLC). Tislelizumab is a programmed cell death 1 (PD-1) antibody that functions as an immune checkpoint inhibitor. Recombinant human endostatin (also known as Endostar) is a multiple-target angiogenesis inhibitor that blocks proliferation and abnormal angiogenesis of tumor endothelial cells by limiting endothelial cell proliferation and migration and inducing endothelial cell apoptosis.
- Other names
- rh-endostatin
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + recombinant human endostatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + recombinant human endostatin.